JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. (2019)
Attributed to:
Addressing the funding gap to advance early stage healthcare research at the University of Sheffield
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/jlb.5ru0519-145r
PubMed Identifier: 31313387
Publication URI: http://europepmc.org/abstract/MED/31313387
Type: Journal Article/Review
Volume: 106
Parent Publication: Journal of leukocyte biology
Issue: 5
ISSN: 0741-5400